Search This Blog

Tuesday, March 27, 2012

Oracle Announces Next Generation of Oracle® Health Sciences Clinical Development Analytics

Note to visitors: The Palo-Negro-Blog is no longer being actively maintained.  For more up-to-date news and information, please visit the successor blogs:  http://JBK-BizTech.blogspot.com and http://JBK-Current-Events.blogspot.com

Oracle Announces Next Generation of Oracle® Health Sciences Clinical Development Analytics

New Features Expand Visibility into Clinical Programs to Help Increase Productivity and Clinical Effectiveness while Helping to Reduce Costs

DIA Annual EuroMeeting, Copenhagen, Denmark – March 27, 2012

News Facts

Focused on helping health sciences organizations increase the productivity and effectiveness of their product development programs, Oracle Health Sciences today introduced the newest version of Oracle® Health Sciences Clinical Development Analytics.
Driven by input from industry partners, the comprehensive business intelligence application includes new functionality that expands visibility into clinical programs and studies, improves the quality and timeliness of clinical trial data and helps to simplify and prioritize the rapidly expanding responsibilities of study managers, clinical data managers, and site monitors.
The enhanced solution helps to increase resource utilization by delivering advanced dashboards specifically tailored to clinical trial roles. It features expanded drill-down functionality and key performance indicators that identify areas requiring action or attention, such as targeting underperforming sites.
The solution enables organizations to merge data from multiple clinical trial sources, providing a unified view across operational systems on a single screen. New de-duplication technology supports reports that combine both clinical operations and data management information to monitor enrollment progress, optimize productivity at site visits and help to reduce monitoring-related travel expenses.
Oracle Health Sciences Clinical Development Analytics also delivers visibility across the entire portfolio of clinical trials, which enables greater insight into subject recruitment and site performance to empower managers and clinical monitors to better target resources to key sites which will help accelerate trial completion.
With more than 100 pre-built reports and over 500 pre-built measurements and attributes for custom reporting, Oracle Health Sciences Clinical Development Analytics can provide immediate business benefit out of the box, while providing an extensible framework for adding additional metrics aligned to targeted business processes.
    • To enable anytime, anywhere access, the solution can be used in conjunction with Oracle Business Intelligence Mobile application for Apple iPhone and iPad to give mobile users access to the latest performance management information.

Supporting Quote

“Clinical trial sponsors and their CRO partners, navigating increasingly complex and lengthy development cycles, are intently focused on improving data quality and clinical program productivity while reducing costs,” said Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences. “The newest version of Oracle Health Sciences Clinical Development Analytics, which features integrated content, expanded dashboards, and optimized reporting, delivers the insight that study sponsors, managers, and monitors require to achieve these goals and accelerate the delivery of new products to the market.”

Supporting Resources

About Oracle

Oracle engineers hardware and software to work together in the cloud and in your data center.  For more information about Oracle (NASDAQ:ORCL), visit www.oracle.com.

About Oracle in Industries

Oracle industry solutions leverage the company’s best-in-class portfolio of products to address complex business processes relevant to health sciences, helping speed time to market, reduce costs, and gain a competitive edge.

Trademark

Oracle and Java are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.
# # #

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.